Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Research & Development history
Currency unavailable · from the income statement
No Research & Development data reported for this period type.
Research & Development vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M USD | -8.7% | +56.3% | 4685.4% |
| LTM Sep 2026 | $259.72M USD | +46.3% | +43.1% | 287.0% | |
| LTM Jun 2026 | $175.16M USD | +21.8% | +8.1% | 62.1% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $153.74M USD | +46.0% | +182.5% | — |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M USD | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €39.31M EUR | +49.4% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +33.9% | +15.3% | 287.0% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.